Case series of cerebral infarction with Trousseau's syndrome associated with malignant gynecological tumors.

The association between neoplastic disease and thromboembolic disorders was first recognized by Trousseau in 1865. Blood coagulation abnormalities have been reported in the majority of patients with cancer, including those with ovarian carcinoma. However, Trousseau's syndrome (TS) has rarely been reported in women with ovarian carcinoma. We herein report a case series of TS, notably in the brain, in association with gynecological malignant disease, and emphasize the difficulties associated with the management of these thromboembolic effects. The aim of this study was to present our experience with 5 TS patients whose condition was effectively controlled through treatment of the primary malignant disease. Therefore, we suggest that patients with TS may be cured by tumor resection, even if they have severe thromboembolic disease, such as cerebral or pulmonary infarction.

[1]  A. Varki,et al.  Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. , 2011, Blood.

[2]  D. Cordato,et al.  Stroke risk factor, pattern and outcome in patients with cancer , 2006, Acta neurologica Scandinavica.

[3]  P. Tarsia,et al.  The heparins and cancer: review of clinical trials and biological properties , 2004, Vascular medicine.

[4]  L. Deangelis,et al.  Stroke in patients with cancer , 2004, Neurology.

[5]  L. Zacharski,et al.  Low-molecular-weight heparin in oncology. , 2003, Anticancer research.

[6]  Yves Gruel,et al.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. , 2002, Archives of internal medicine.

[7]  M. Levine.  Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. , 2002, Cancer treatment reviews.

[8]  S. Kayser,et al.  Therapeutic Equivalency of Low-Molecular-Weight Heparins , 2002, The Annals of pharmacotherapy.

[9]  A A Rimm,et al.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. , 1999, Medicine.

[10]  D. Green,et al.  Low‐molecular‐weight heparin in the management of Tyrousseau's syndrome , 1997, Cancer.

[11]  G. Feuer,et al.  Lower limb ischemic venous thrombosis in patients with advanced ovarian carcinoma. , 1993, Gynecologic oncology.

[12]  M. Liepman,et al.  Safety and efficacy of long‐term oral anticoagulation in cancer patients , 1987, Cancer.

[13]  W. Bell,et al.  Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. , 1985, The American journal of medicine.

[14]  E. O'Sullivan,et al.  The Hypercoagulable State and Pulmonary Embolism in Patients With Ovarian Carcinoma , 1978, The Australian & New Zealand journal of obstetrics & gynaecology.

[15]  S. Vernon.  Trousseau's syndrome: thrombophlebitis with carcinoma. , 1961, The Journal of abdominal surgery.

[16]  K. Tanabe,et al.  Trousseau syndrome with nonbacterial thrombotic endocarditis in a patient with uterine cancer. , 2013, Internal medicine.

[17]  S. Coughlin,et al.  neutrophils in a murine model of Trousseau syndrome Carcinoma mucins trigger reciprocal activation of platelets and , 2011 .

[18]  J. Levin,et al.  Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. , 1977, Medicine.

[19]  A. Trousseau.  Phlegmasia alba dolens. , 1865 .